New progress in the role of microRNAs in the diagnosis and prognosis of triple negative breast cancer

Abstract

Triple negative breast cancer is distinguished by its high malignancy, aggressive invasion, rapid progression, easy recurrence, and distant metastases. Additionally, it has a poor prognosis, a high mortality, and is unresponsive to conventional endocrine and targeted therapy, making it a challenging problem for breast cancer treatment and a hotspot for scientific research. Recent research has revealed that certain miRNA can directly or indirectly affect the occurrence, progress and recurrence of TNBC. Their expression levels have a significant impact on TNBC diagnosis, treatment and prognosis. Some miRNAs can serve as biomarkers for TNBC diagnosis and prognosis. This article summarizes the progress of miRNA research in TNBC, discusses their roles in the occurrence, invasion, metastasis, prognosis, and chemotherapy of TNBC, and proposes a treatment strategy for TNBC by interfering with miRNA expression levels.

Exploring miRNA‑target gene profiles associated with drug resistance in patients with breast cancer receiving neoadjuvant chemotherapy

“…However, the mechanisms underlying NAC resistance remain unclear and are likely to be multifactorial. Recently, several microRNAs (miRNAs) were discovered to be significantly upregulated in drug-resistant cancer cells, emerging as potential biomarkers for evaluating tumor responses to treatment ( 9 , 10 ). MiRNAs regulate gene expression by targeting multiple mRNAs for degradation or translational inhibition ( 11 ).…”

Gold Nanoparticles Downregulate IL-6 Expression/Production by Upregulating microRNA-26a-5p and Deactivating the RelA and NF-κBp50 Transcription Pathways in Activated Breast Cancer Cells

“…Dysmodulation of miRNAs can lead to aberrant expression of target genes involved in cell proliferation, apoptosis, migration, and invasion, thereby promoting BC initiation and progression [20][21][22][23]. Certain miRNAs have been identified as potential diagnostic and prognostic biomarkers in BC, with their expression patterns associated with specific subtypes and clinical outcomes [24,25]. Moreover, miRNAs have shown promise as therapeutic targets, as modulation of their expression can influence tumor growth and sensitize cancer cells to treatment [26][27][28][29].…”